









Markets
/
Stocks
/
nasdaq-vrca
/

Verrica Pharmaceuticals Inc

VRCA

6.910USD

+0.300+4.54%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

65.58MMarket Cap

LossP/E TTM



Verrica Pharmaceuticals Inc

6.910

+0.300+4.54%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Verrica Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Verrica Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.50.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Verrica Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

90 / 159

Overall Ranking

244 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Verrica Pharmaceuticals Inc Highlights

StrengthsRisks

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Growing

The company is in a growing phase, with the latest annual income totaling USD 7.57M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 7.57M.

Undervalued

The company’s latest PE is -2.42, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.04M shares, decreasing 13.99% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 29.19K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.95.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

16.500

Target Price

+149.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Verrica Pharmaceuticals Inc is 7.40, ranking 116 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 14.34M, representing a year-over-year increase of 905.39%, while its net profit experienced a year-over-year increase of 98.80%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

6.56

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Verrica Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Verrica Pharmaceuticals Inc is 7.95, ranking 38 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -2.42, which is -98.79% below the recent high of -0.03 and -31.69% above the recent low of -3.18.

Score

Industry at a Glance

Previous score

7.95

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 90/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Verrica Pharmaceuticals Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 19.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

16.500

Target Price

+149.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Verrica Pharmaceuticals Inc

VRCA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Verrica Pharmaceuticals Inc is 6.87, ranking 100 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.95 and the support level at 6.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.194

Sell

RSI(14)

42.254

Neutral

STOCH(KDJ)(9,3,3)

22.268

Neutral

ATR(14)

0.464

Low Volatility

CCI(14)

-123.494

Sell

Williams %R

77.330

Sell

TRIX(12,20)

-0.467

Sell

StochRSI(14)

47.433

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

7.100

Sell

MA10

7.162

Sell

MA20

7.464

Sell

MA50

7.779

Sell

MA100

5.924

Buy

MA200

5.955

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Verrica Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 19.01%, representing a quarter-over-quarter decrease of 27.07%. The largest institutional shareholder is The Vanguard, holding a total of 138.19K shares, representing 0.86% of shares outstanding, with 66.41% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Manning (Paul B.)

4.56M

+45.27%

BKB Growth Investments LLC

3.35M

+460.29%

Caligan Partners, LP

923.91K

Affinity Asset Advisors LLC

707.34K

Armistice Capital LLC

639.19K

-28.03%

Boothbay Fund Management, LLC

280.73K

Stalfort (John A)

187.38K

+14.56%

Rieger (Jayson)

183.30K

+105.98%

The Vanguard Group, Inc.

Star Investors

225.21K

+3.86%

Millennium Management LLC

71.99K

-20.64%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Verrica Pharmaceuticals Inc is 1.60, ranking 149 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.